Alexander Mathioudakis (Liverpool, United Kingdom), Ian M. Adcock (London, United Kingdom)
Effects of tiotropium on lung function in current smokers and never smokers with asthma
Makoto Yoshida (Fukuoka, Japan), Makoto Yoshida, Tomoaki Iwanaga, Hiromasa Inoue
|   |
Asthma medication during pregnancy: A cohort study in EFEMERIS database
Alain Didier (Toulouse, France), Alain Didier, Anna-belle Beau, Isabelle Lacroix, Caroline Hurault-Delarue, Jean-louis Montastruc, Christine Damase-Michel
| |
Efficacy of omalizumab in allergic asthma by asthma severity and eosinophilic status
Karin Rosen (South San Francisco, United States of America), Nicola A. Hanania, Benjamin Trzaskoma, Karin Rosén, Volkan Manga, Theodore A. Omachi
| |
In vitro comparison of dose accuracy of two budesonide/formoterol dry powder inhalers
Jussi Haikarainen (Espoo, Finland), Jussi Haikarainen, Anita Happonen, Tero Löytänä
| |
A national database study of the effectiveness of switching real-life asthma patients to fostair
Graham Devereux (Aberdeen, United Kingdom), Markus Steiner, Steve Turner, Graham Devereux
| |
GLISTEN Study subanalysis: Glycopyrronium differentially improves lung function, health status and rescue medication use when added to salmeterol/fluticasone in COPD severity groups
Peter Frith (Daw Park, Australia), Peter Frith, Philip Thompson, Christina Frenzel, Nicol Kurstjens, GLISTEN Study Group
| |
Efficacy of fluticasone furoate (FF)/vilanterol (VI) or FF alone in asthma patients with differing eosinophil (eos) levels
Ashley Woodcock (Manchester, United Kingdom), Ashley Woodcock, Loretta Jacques, David Leather, Richard Forth
| |
The fixed-dose combination of tiotropium + olodaterol has a rapid onset of action in patients with COPD
Gary T. Ferguson (Livonia, United States of America), Gary T. Ferguson, Emilio Pizzichini, Matjaž Fležar, Lars Grönke, Lawrence Korducki
| |
Tiotropium + olodaterol fixed-dose combination shows clinically meaningful improvements in quality of life versus placebo
Dave Singh (Manchester, United Kingdom), Dave Singh, Gary T. Ferguson, Josef Bolitschek, Lars Grönke, Christoph Hallmann, Nathan Bennett, Roger Abrahams, Olaf Schmidt, Leif Bjermer
| |
Minimal effect of inhaled corticosteroids (ICS) on blood eosinophil count in steroid-naïve COPD patients
James Kreindler (Merion Station, United States of America), James Kreindler, Nicholas Locantore, Michael Watkins, Sally Lettis, Ruth Tal-Singer
| |
Efficacy of aclidinium/formoterol fixed-dose combination versus salmeterol/fluticasone in COPD
Claus Vogelmeier (Marburg, Germany), Claus Vogelmeier, Pier Luigi Paggiaro, Jordi Dorca, Pawel Sliwinski, Marcel Mallet, Anne-Marie Kirsten, Beatriz Seoane, Rosa Maria Segarra, Anne Leselbaum, Esther Garcia Gil
| |
Pharmacokinetic interaction of glycopyrronium bromide pMDI and formoterol pMDI: A randomized, open-label, single-dose, 4-way cross-over study
Fabrizia Mariotti (Parma, Italy), Sara Collarini, Anna Compagnoni, Dario Cuomo, Fabrizia Mariotti, Annamaria Muraro, Daniela Acerbi
| |
The economical effect of inhaler in patients with early chronic obstructive pulmonary disease
Ji Young Yhi (Seoul, Republic of Korea), Ji Young Yhi, Tae-Hyung Kim, Jinkyeong Park, Chin Kook Rhee, Kwang Ha Yoo
| |
Influence of inhaled glucocorticosteroids on course of the bronchiectasis
Eduard Khodosh (Kharkiv, Ukraine), Eduard Khodosh, Peter Poteiko, Valeriy Krutko, Dmitriy Khoroshun
| |
The antiinflammatory and antioxidant effect of tiotropium bromide in subacute cigarette exposure mouse model
Aysun Şengül (Kocaeli, Turkey), Aysun Sengul, Meyrem Ozkan, Ceyla Eraldemir, Leman Huseynova, Doga Ozsoy, Firuzan Akar
| |
Once-daily QVA149 improves lung function and health status versus twice-daily salmeterol/fluticasone (SFC) in symptomatic GOLD B and GOLD D COPD patients: LANTERN/ILLUMINATE pooled analysis
Claus Vogelmeier (Marburg, Germany), Claus Vogelmeier, Nanshan Zhong, Karen Mezzi, Robert Fogel, Donald Banerji
| |
QVA149 is more efficacious than tiotropium and salmeterol/fluticasone combination (SFC) in improving patient-reported outcomes and lung function in COPD patients with moderate-to-severe baseline dyspnoea: The IGNITE trials
Donald A. Mahler (Lebanon, United States of America), Donald Mahler, Dorothy Keininger, Robert Fogel, Karen Mezzi, Donald Banerji
| |
Pharmacokinetic studies for the estimation of bioequivalence of two DPIs containing budesonide and formoterol
Katerina Athanassiou (Pikermi, Greece), Katerina Athanassiou, Luigi Silvestro, Simona Rizea Savu
| |